利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

114 条记录 (耗时 0.016 秒)

    NOVEL INHIBITORS OF PROTEIN KINASE C EPSILON SIGNALING
    1.
    发明申请
    NOVEL INHIBITORS OF PROTEIN KINASE C EPSILON SIGNALING 审中-公开
    蛋白激酶C EPSILON信号的新型抑制剂

    公开(公告)号：WO2014207213A1

    公开(公告)日：2014-12-31

    申请号：PCT/EP2014/063723

    申请日：2014-06-27

    申请人： MEDIZINISCHE UNIVERSITÄT INNSBRUCK ,  UNIVERSITÄT INNSBRUCK ,  GAUSE INSTITUTE OF NEW ANTIBIOTICS

    发明人： HOFMANN, Johann ,  LANGER, Thierry ,  KIRCHMAIR, Johannes ,  RECHFELD, Florian ,  GRUBER, Peter ,  BÖHLER, Markus ,  HECHENBERGER, Georg ,  GARCZARCZYK, Dorota ,  PREOBRAZHENSKAYA, Maria N. ,  LAPA, Gennady B.

    IPC分类号： A61K31/4743 ,  C07D495/04 ,  C07D495/14 ,  A61P35/00

    CPC分类号： C07D495/14 ,  A61K31/4743 ,  C07D495/04

    摘要： The present invention relates to novel inhibitors of protein kinase C epsilon (PKCε) signaling, including in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these inhibitors, and their use in the treatment or prevention of disorders such as, e.g., a cardiovascular disorder, cardiac hypertrophy, heart failure, anxiety, pain, chronic pain, migraine, an allergy, an inflammatory disorder, an autoimmune disorder, diabetes, diabetic complications, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic neuropathy, cancer, metastatic cancer, drug-resistant cancer, stomach cancer, lung cancer, thyroid cancer, colon cancer, breast cancer, a neurological disorder, Alzheimer's disease, Parkinson's disease, bipolar disorder, stroke, alopecia, or alcoholism.

    摘要翻译： 本发明涉及蛋白激酶Cε（PKC）信号传导的新型抑制剂，特别包括本文所述和定义的式（I）化合物，包含这些抑制剂的药物组合物及其在治疗或预防疾病中的用途 例如心血管疾病，心脏肥大，心力衰竭，焦虑，疼痛，慢性疼痛，偏头痛，过敏，炎症性疾病，自身免疫性疾病，糖尿病，糖尿病并发症，糖尿病性视网膜病变，糖尿病性肾病，糖尿病性心肌病，糖尿病 神经病，癌症，转移性癌症，耐药性癌症，胃癌，肺癌，甲状腺癌，结肠癌，乳腺癌，神经障碍，阿尔茨海默病，帕金森病，双相情感障碍，中风，脱发或酒精中毒。

    PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR THE MEDICAL MANAGEMENT OF ANGIOGENESIS AND HYPOVASCULARITY
    2.
    发明申请
    PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR THE MEDICAL MANAGEMENT OF ANGIOGENESIS AND HYPOVASCULARITY 审中-公开
    包含LIGNANS及其衍生物的药物组合物用于血管生成和血管生成的医学管理

    公开(公告)号：WO2011089161A1

    公开(公告)日：2011-07-28

    申请号：PCT/EP2011/050701

    申请日：2011-01-19

    申请人： MEDIZINISCHE UNIVERSITÄT WIEN ,  UNIVERSITÄT INNSBRUCK ,  MEDIZINISCHE UNIVERSITÄT INNSBRUCK ,  BERNHARD, David ,  STUPPNER, Hermann ,  SCHWAIGER, Stefan ,  WIEDEMANN, Dominik ,  UNTERGASSER, Gerold

    发明人： BERNHARD, David ,  STUPPNER, Hermann ,  SCHWAIGER, Stefan ,  WIEDEMANN, Dominik ,  UNTERGASSER, Gerold

    IPC分类号： A61K31/341 ,  A61P17/02 ,  A61P9/10

    CPC分类号： A61K31/341

    摘要： The present invention relates to a pharmaceutical composition for stimulating angiogenesis and/or the treatment or prevention of hypovascυlarity and/or the prevention and/or treatment of an angiogenic disorder/disease, whereby the composition comprises specific compounds which may be obtained from Leontopodium alpinum Cass, (Edelweiss). These compounds relate to lignan compounds as shown in herein disclosed formula 1. A preferred compound in this context is leologin - IUPAC name [(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4- dimethoxyphenyl)tetxahydrofuran-3-yl]methyl (2Z)-2-methylbut-2-enoat], and even more particularly 5-methoxy-leoligin (IUPAC name: [(25,3R,4R)-4-(3,4-dimethoxybenzyl)-2- (3,4,5-trimethoxyphenyl)tetrahydrofuran-3-yl]methyl-(2Z)-2-methylbut-2-enoat) and derivatives thereof. Corresponding means and methods in respect of medical uses of these compounds are described. The compounds provided herein may particularly be useful in the treatment of wound healing, in particular traumatic wounds (like, but not limited to surface and skin wounds), non-diabetic retinopathy, vascular obliteration. The compounds derived from Leontopodium alpinum Cass. (Edelweiss) as described herein are also useful in the re-vascularization of tissue after amputation as well during or after transplantation of tissues or organs. These compounds are also useful in the medical intervention of arterio- and veno-microvasculopathy of blood vessels, in particular retinal microvasculopathy, arterio- and veno-microangiopathy that preferably cannot be treated by surgery, in ischemic diseases or ischemic disorders or in the treatment or prevention of necrosis/necrotic events, in particular of ischemic diseases or necrosis/necrotic events that cannot be treated by surgery. These compounds may also be used in the treatment or prevention of stable angina abdominalis, vascular dementia, impotence or penile dysfunction and the like and they may be employed in the reactivation of necrotisising tissue or in the reactivation of hibernating tissue.

    摘要翻译： 本发明涉及用于刺激血管生成和/或治疗或预防血管生成障碍/ /预防和/或治疗血管生成障碍/疾病的药物组合物，其中该组合物包含可从Leontopodium获得的特定化合物 阿尔卑斯卡斯（Edelweiss）。 这些化合物涉及如本文公开的式1所示的木脂素化合物。本文中优选的化合物是Lologin-IUPAC名称[（2S，3R，4R）-4-（3,4-二甲氧基苄基）-2-（3,4 （2Z）-2-甲基丁-2-烯酸]，更特别是5-甲氧基 - 亮氨酸（IUPAC名称：[（25,3R，4R）-4-（3,3-二甲氧基苯基） 4-二甲氧基苄基）-2-（3,4,5-三甲氧基苯基）四氢呋喃-3-基]甲基 - （2Z）-2-甲基丁-2-烯酸酯）及其衍生物。 对这些化合物的医疗用途的相应手段和方法进行了说明。 本文提供的化合物可特别用于治疗伤口愈合，特别是创伤性伤口（例如但不限于表面和皮肤伤口），非糖尿病性视网膜病变，血管闭塞。 衍生自Leontopodium alpinum Cass的化合物。 （Edelweiss）也可用于组织或器官移植期间或之后截肢后组织的再血管化。 这些化合物还可用于血管的动静脉和静脉微血管病变，特别是视网膜微血管病变，优选不能通过手术治疗的动脉和静脉微血管病变，缺血性疾病或缺血性疾病或治疗或 预防坏死/坏死事件，特别是缺血性疾病或不能手术治疗的坏死/坏死事件。 这些化合物也可以用于治疗或预防稳定型心绞痛，血管性痴呆，阳ence或阴茎功能障碍等，并且它们可用于坏死组织的再活化或冬眠组织的再激活。

    ELECTROCHEMICAL CELL
    4.
    发明申请
    ELECTROCHEMICAL CELL 审中-公开
    电化学细胞

    公开(公告)号：WO2015097248A1

    公开(公告)日：2015-07-02

    申请号：PCT/EP2014/079244

    申请日：2014-12-23

    申请人： UNIVERSITÄT INNSBRUCK ,  MEDIZINISCHE UNIVERSITÄT INNSBRUCK

    发明人： KOFLER, Markus ,  DUMPFARTH, Julia ,  GRIMM, Michael ,  GRIMM, Georg ,  FAULAND, Gulnara ,  BECHTOLD, Thomas

    IPC分类号： B01D61/42 ,  B01D61/46 ,  B01D63/08

    CPC分类号： B01D61/427 ,  B01D61/422 ,  B01D61/46 ,  B01D2313/30 ,  B01D2313/345 ,  B01D2325/42 ,  G01N27/283 ,  G01N27/403

    摘要： Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a second separator membrane (S2) arranged between said treatment compartment (T) and said intermediate anodic compartment (A1).

    摘要翻译： 用于通过电 - （端）渗透流处理样品的电化学电池阵列，包括（i）包括阴极室（CC）和阳极室（AC）的电极室，（ii）阴极（C） 布置在阴极室（CC）中，（iii）阳极（A），布置在阳极室（AC）中，（iv）中间阴极室（C1）（v）中间阳极室（A1） （iv）布置在所述阴极室（CC）和所述第一中间阴极室（C1）之间的第一选择膜（M1）（v），布置在所述阳极室（AC）和所述第一中间阴极室 中间阳极室（A1）（vi）用于所述样品的处理室（T）布置在所述中间阴极室（C1）和所述中间阳极室（A1）之间，还包括在所述处理室 （T）和所述中间阴极compart （C1）和布置在所述处理室（T）和所述中间阳极室（A1）之间的第二隔膜（S2）。

    METHOD FOR DECOMPOSING SULFUR HEXAFLUORIDE
    5.
    发明申请
    METHOD FOR DECOMPOSING SULFUR HEXAFLUORIDE 审中-公开

    公开(公告)号：WO2023031317A1

    公开(公告)日：2023-03-09

    申请号：PCT/EP2022/074290

    申请日：2022-09-01

    申请人： UNIVERSITÄT INNSBRUCK

    发明人： ROTERING, Philipp ,  DIELMANN, Fabian

    IPC分类号： C01B17/45 ,  C07F9/02 ,  C07F9/576

    摘要： A method for decomposing SF6 comprising the step of contacting SF6 with a phosphine PR1R2R3, wherein the phosphine PR1R2R3 is contacted with SF6 in the presence of a light source, wherein (a) the phosphine PR1R2R3 is an alkyl phosphine and R1, R2 and R3 are each C1 to C12 alkyl groups, wherein in addition a photosensitizer comprising an aryl group is present; or (b) the phosphine PR1R2R3 is an aryl phosphine and at least one of R1, R2 or R3 is selected from the group consisting of phenyl, C1 to C12-alkyl substituted phenyl, C1 to C12- alkyloxy substituted phenyl, NR4R5 substituted phenyl, aryl substituted phenyl and combinations thereof, wherein R4 and R5 are each independently selected from H and C1 to C12-alkyl.

    EXTRACT WITH ANTI-INFLAMMATORY EFFECT
    6.
    发明申请
    EXTRACT WITH ANTI-INFLAMMATORY EFFECT 审中-公开

    公开(公告)号：WO2022263580A1

    公开(公告)日：2022-12-22

    申请号：PCT/EP2022/066436

    申请日：2022-06-15

    申请人： MEDIZINISCHE UNIVERSITÄT INNSBRUCK ,  MCI - MANAGEMENT CENTER INNSBRUCK ,  ADSI - AUSTRIAN DRUG SCREENING INSTITUTE GMBH

    发明人： HUBER, Lukas A. ,  VALOVKA, Taras ,  GRIESBECK, Christoph ,  TROCKENBACHER, Alexander ,  LEITNER, Peter ,  BONN, Günther K. ,  JAKSCHITZ, Thomas ,  GSTIR, Ronald

    IPC分类号： A61K36/05 ,  A61K36/02 ,  A61P29/00

    摘要： The present invention relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria. The invention further relates to compositions comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS. The invention further relates to pharmaceutical compositions comprising the anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient. The invention further relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof or a pharmaceutical composition comprising an anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient for use as a medicament, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria. The invention further relates to compositions comprising an anti- inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria.

    BIOMARKER FOR MONITORING CORONAVIRUS DISEASE 2019
    7.
    发明申请
    BIOMARKER FOR MONITORING CORONAVIRUS DISEASE 2019 审中-公开

    公开(公告)号：WO2022258252A1

    公开(公告)日：2022-12-15

    申请号：PCT/EP2022/060885

    申请日：2022-04-25

    申请人： MEDIZINISCHE UNIVERSITÄT INNSBRUCK

    发明人： HAYBÄCK, Johannes ,  SCHATZ, Christoph ,  VON LAER, Meike Dorothee

    IPC分类号： G01N33/569 ,  C12Q1/70

    摘要： The present invention relates to a method of monitoring the course of Coronavirus disease 2019 (COVID-19) in a patient suffering from COVID-19. Further, the present invention relates to a method of prognosing the severity of Coronavirus disease 2019 (COVID-19) in a patient. Furthermore, the present invention relates to a method of determining whether a patient suffering from Coronavirus disease 2019 (COVID-19) responds to a therapeutic treatment of COVID-19. In addition, the present invention relates to a kit useful for conducting these methods.The biomarkers for these purposes are a eukaryotic Initiation Factor (elF), a eukaryotic Elongation Factor (eEF), Mitochondrial Ribosome Recycling Factor (MRRF) and ATP-binding cassette sub-family E member 1 (ABCE1).